AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Sun Pharma Advanced Research Company Ltd. Call Transcript 2020

Feb 13, 2020

60740_rns_2020-02-13_a67eaf9b-69ef-4cdf-8771-1e3e349554a4.pdf

Call Transcript

Open in viewer

Opens in your device viewer

FOR IMMEDIATE RELEASE

==> picture [142 x 65] intentionally omitted <==

SPARC to Provide Update on Taclantis[TM] NDA

MUMBAI – February 13, 2020 , Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) on Monday, March 2, 2020, will host a conference call to provide an update on Taclantis[TM] (Paclitaxel Injection Concentrate for Suspension) NDA (New Drug Application) status. This conference call, scheduled at 4:00 PM IST, will be reachable through an audio dial-in.

Audio conference Participants can dial-in on the number below:

+91 22 6280 1278 Universal Dial In +91 22 7115 8179 1 800 120 1221 India National Toll Free 1 800 266 1221 International Toll Free Hong Kong 800964448 Singapore 8001012045 UK 08081011573 USA 18667462133

To participate in the conference call, please dial in the number provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call.

About SPARC (CIN: L73100GJ2006PLC047837):

Sun Pharma Advanced Research Company Ltd. (SPARC) is a global pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC aims to consistently lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at www.sparc.life

Contacts: